CLEC12A and acute myeloid leukemia: CLL-1 is proposed as a CAR-T cell therapy target in AML because its expression on primary AML lines varies from 77.5%–90% and also in LSCs, whereas HSCs barely express CLL-1 (2.5%) (Ma et al., 2019).